Summit Therapeutics PLC (SMMT) Research Coverage Started at HC Wainwright
HC Wainwright started coverage on shares of Summit Therapeutics PLC (NASDAQ:SMMT) in a research note issued to investors on Friday morning. The brokerage issued a buy rating and a $26.00 price objective on the stock.
A number of other equities analysts also recently commented on SMMT. Zacks Investment Research downgraded shares of Summit Therapeutics PLC from a hold rating to a strong sell rating in a research note on Friday, May 27th. Canaccord Genuity reaffirmed a buy rating and set a $14.00 price target on shares of Summit Therapeutics PLC in a research note on Friday, June 3rd. Oppenheimer Holdings Inc. reaffirmed a buy rating on shares of Summit Therapeutics PLC in a research note on Thursday, June 16th. Finally, Janney Montgomery Scott initiated coverage on shares of Summit Therapeutics PLC in a research note on Tuesday, June 21st. They set a buy rating on the stock. Six investment analysts have rated the stock with a buy rating, The stock currently has a consensus rating of Buy and a consensus price target of $19.40.
Shares of Summit Therapeutics PLC (NASDAQ:SMMT) opened at 7.7999 on Friday. Summit Therapeutics PLC has a one year low of $4.26 and a one year high of $12.78. The stock has a 50 day moving average of $6.74 and a 200-day moving average of $7.50. The stock’s market capitalization is $95.89 million.
An institutional investor recently bought a new position in Summit Therapeutics PLC stock. Granite Point Capital Management L.P. acquired a new stake in Summit Therapeutics PLC (NASDAQ:SMMT) during the second quarter, according to its most recent 13F filing with the Securities and Exchange Commission. The firm acquired 112,676 shares of the company’s stock, valued at approximately $891,000. Granite Point Capital Management L.P. owned approximately 0.92% of Summit Therapeutics PLC at the end of the most recent reporting period.
Summit Therapeutics PLC Company Profile
Summit Therapeutics plc, formerly Summit Corporation plc, is a United Kingdom-based biopharmaceutical company. The Company is focused on the discovery, development and commercialization of medicines for indications for which there are no existing or only inadequate therapies. The Company is conducting clinical programs focused on the genetic disease Duchenne muscular dystrophy (DMD) and the infectious disease Clostridium difficile infection (CDI).
Receive News & Ratings for Summit Therapeutics PLC Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Summit Therapeutics PLC and related companies with Analyst Ratings Network's FREE daily email newsletter.